Intuitive announced that the U.S. Food and Drug Administration has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and internal mammary artery mobilization for cardiac revascularization.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target raised to $712 from $686 at Barclays
- Intuitive Surgical Earnings Call: Growth Surges, Margins Pinched
- Intuitive Surgical’s JURA Feasibility Study: Early Imaging Data With Long-Term Upside for Investors
- Intuitive says over 20M patients operated on with use of da Vinci systems
- Morning Movers: Nvidia up after report of potential China move on H200 chips